This fixed-dose combination contains Dapagliflozin (an SGLT2 inhibitor) and Metformin (a biguanide). It is indicated for improving glycemic control in adults with type 2 diabetes mellitus. The combination enhances glucose excretion via the kidneys and decreases hepatic glucose production while improving insulin sensitivity.
Reviews
There are no reviews yet.